DarioHealth (DRIO) Corporate presentation summary
Event summary combining transcript, slides, and related documents.
Corporate presentation summary
16 Apr, 2026Platform overview and market opportunity
AI-powered, multi-condition platform addresses cardiometabolic, behavioral, and musculoskeletal care, supporting up to 6+ conditions with bundled pricing at $74 per engaged member per month.
Serviceable addressable market estimated at over $250 billion, with rapid expansion enabled by platform architecture.
76% of U.S. adults have a chronic disease, and 51% have two or more comorbid conditions, highlighting significant demand.
Blue-chip client base includes 160+ clients, such as Fortune 100 employers and national health plans.
Channel partnerships provide access to approximately 116 million covered lives, accelerating market penetration.
Product features and engagement
Integrated digital platform combines connected devices, AI-powered coaching, community support, and clinical services for personalized care.
Comprehensive support for diabetes, hypertension, weight management, musculoskeletal, behavioral health, and GLP-1 management.
Average member retention rate after 12 months is 75%, with members using an average of 2.4 solutions.
Proprietary AI model achieves 90% accuracy in predicting blood sugar fluctuations and delivers a 20% increase in engagement for hypertension management.
100+ published peer-reviewed studies validate clinical outcomes and ROI.
Financial performance and growth
FY2025 revenue reached $22.4M, with Q4 resuming sequential growth and a 10% organic YoY increase.
Non-GAAP gross margin for B2B2C business is approximately 80%, with a 28% YoY reduction in GAAP OpEx.
$12.9M in new and soon-to-be-closed ARR contracts, contributing to 2026-2027 growth.
$122M pipeline of commercial opportunities, with 70% focused on multi-condition contracts.
Targeting cashflow breakeven by mid-2027, with a 30% decrease in non-GAAP operating loss expected in 2026.
Latest events from DarioHealth
- AI-driven, multi-condition platform achieves clinical validation, strong growth, and high client retention.DRIO
Corporate presentation10 Apr 2026 - Registering up to $100M in securities to support growth and innovation in digital health.DRIO
Registration filing19 Mar 2026 - Record new business, margin expansion, and a $122M pipeline set up for accelerated 2026 growth.DRIO
Q4 202519 Mar 2026 - B2B2C revenue surged 315% year-over-year, driving margin gains and a path to breakeven by 2025.DRIO
Q2 20242 Feb 2026 - Q3 revenue up 111% YoY, but cash shortfall and delisting risk threaten future viability.DRIO
Q3 202416 Jan 2026 - Amendment updates auditor consent for shelf registration; no changes to prospectus content.DRIO
Registration Filing29 Dec 2025 - 2024 revenue up 32.9% to $27M, net loss narrowed, breakeven targeted for 2025.DRIO
Q4 202426 Dec 2025 - Annual meeting seeks approval for director elections, auditor, equity plan, and charter amendment.DRIO
Proxy Filing22 Dec 2025 - 52.1M shares registered for resale; no proceeds to company; focus on AI-driven digital health.DRIO
Registration Filing16 Dec 2025